Table 3 Main VWF/ADAMTS13 features at... | American Society of Hematology

Table 3

Main VWF/ADAMTS13 features at presentation and at initial remission of the first TMA attack of the 6 relapsing patients during the 18-month follow-up

Patient no.	VWFAg, IU/dL	ADAMTS13 Ag, ng/mL	ADAMTS13 inhibitor titer	Anti-ADAMTS13 IgG titer, 1/dilution	ADAMTS13 activity, %; inhibitor in remission
6	140	450	+++	200	< 5; ++
13	180	145	+++	800	< 5; ++
14	245	75	+	400	< 5; +
16	140	1010	+++	800	< 5; ++
21	70	300	+++	1600	15; −
27	140	160	−	200	< 5; −

Patient no.	VWFAg, IU/dL	ADAMTS13 Ag, ng/mL	ADAMTS13 inhibitor titer	Anti-ADAMTS13 IgG titer, 1/dilution	ADAMTS13 activity, %; inhibitor in remission
6	140	450	+++	200	< 5; ++
13	180	145	+++	800	< 5; ++
14	245	75	+	400	< 5; +
16	140	1010	+++	800	< 5; ++
21	70	300	+++	1600	15; −
27	140	160	−	200	< 5; −

Anti-ADAMTS13 IgM titer and anti-ADAMTS13 IgA titer equal 0 for all patients listed in this table.

+++ indicates high; ++, medium; +, low; −, negative.